Last reviewed · How we verify
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
This phase I/II trial studies the side effects and how well localized radiation therapy or recombinant interferon beta and avelumab with or without cellular adoptive immunotherapy works in treating patients with Merkel cell carcinoma that has spread to other parts of the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Interferon beta is a substance that can improve the body's natural response and may interfere with the growth of tumor cells. Monoclonal antibodies, such as avelumab, may help T lymphocytes kill tumor cells. For cellular adoptive immunotherapy, specific white blood cells are collected from the patient's blood and treated in the laboratory to recognize Merkel cell carcinoma. Infusing these cells back into the patient may help the body build an effective immune response to kill Merkel cell carcinoma. Giving localized radiation therapy or recombinant interferon beta and avelumab with or without cellular adoptive immunotherapy may be a better treatment for Merkel cell carcinoma.
Details
| Lead sponsor | Fred Hutchinson Cancer Center |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | TERMINATED |
| Enrolment | 8 |
| Start date | Fri Nov 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Merkel Cell Polyomavirus Infection
- Stage IV Merkel Cell Carcinoma AJCC v7
Interventions
- Avelumab
- Laboratory Biomarker Analysis
- MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells
- Radiation Therapy
- Recombinant Interferon Beta
Countries
United States